FDA
OrganizationRelationship Network
HOUSE_OVERSIGHT_029092.jpg
An email thread from February 2017 between Jeremy Rubin and Jeffrey Epstein (using the alias jeevacation@gmail.com). Rubin updates Epstein on Bitcoin-related political developments involving Trump appointees, his research at Stanford, and his current teaching engagement at Digital Garage in Tokyo. Epstein inquires about Rubin's location and confirms he is in New York, not Japan.
HOUSE_OVERSIGHT_029090.jpg
An email thread from February 2017 between Jeremy Rubin and Jeffrey Epstein (via jeevacation@gmail.com). Rubin provides Epstein with detailed updates regarding the Trump administration's stance on Bitcoin, his recent presentation at Stanford, and his current work teaching Bitcoin to engineers in Japan in collaboration with DG. Epstein briefly responds to ask how long Rubin will be in Japan.
HOUSE_OVERSIGHT_029087.jpg
An email from Jeremy Rubin to Jeffrey E. (Epstein) dated February 1, 2017. Rubin provides updates on the political landscape regarding Bitcoin (mentioning Balaji Srinivasan and Peter Thiel), discusses his recent research presentation at Stanford regarding 'inverse-input contracts,' and describes his current trip to Japan where he is teaching a Bitcoin course to engineers.
HOUSE_OVERSIGHT_024903.jpg
This document is page 87 of a 'Cowen Collaborative Insights' report dated February 25, 2019, analyzing the pharmaceutical market for cannabinoid-based drugs, specifically focusing on GW Pharmaceuticals' Epidiolex and its clinical trials for epilepsy. The text details statistical results from Phase III trials, FDA approval timelines, and efficacy comparisons against placebos. The document bears a 'HOUSE_OVERSIGHT_024903' stamp, indicating it was part of a document production for a congressional investigation, and is watermarked for Michael Cella at Cowen.
HOUSE_OVERSIGHT_024893.jpg
This document is a page from a Cowen 'Collaborative Insights' market report dated February 25, 2019, bearing the Bates stamp HOUSE_OVERSIGHT_024893. It details regulatory crackdowns and guidance regarding CBD (cannabidiol) products in Maine, New York, and North Carolina, specifically noting that these states are aligning with FDA guidance to prohibit CBD in food additives while creating specific frameworks for supplements or topicals. While part of the House Oversight production (likely related to financial records), the text itself discusses cannabis industry regulations and does not mention Jeffrey Epstein or his associates.
HOUSE_OVERSIGHT_024892.jpg
This document is page 76 of a Cowen Collaborative Insights report dated February 25, 2019. It details regulatory challenges and updates regarding CBD and hemp products, specifically focusing on FDA regulations and state-level legislation in California (Assembly Bill 2914). The document bears a 'HOUSE_OVERSIGHT' footer, suggesting it was part of a document production for a congressional investigation, though the content itself is strictly related to cannabis industry regulation and contains no direct mention of Jeffrey Epstein or his associates.
HOUSE_OVERSIGHT_024891.jpg
This document is a market research report from Cowen Washington Research Group dated February 25, 2019, authored by Assaraf and watermarked for Michael Cella. It analyzes the regulatory landscape for CBD following the passage of the 2018 Farm Bill, specifically highlighting that while hemp was declassified, the FDA (under Commissioner Scott Gottlieb) retains authority over CBD products making health claims or used in food. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, suggesting it was part of a document production for a Congressional investigation.
HOUSE_OVERSIGHT_024880.jpg
This document is page 64 of a Cowen Collaborative Insights market research report dated February 25, 2019. It analyzes the healthcare payor and provider perspectives on CBD oils and medical marijuana, specifically discussing reimbursement challenges with CMS and commercial insurers, as well as policy shifts at Intermountain Healthcare in Utah. The document bears a 'HOUSE_OVERSIGHT_024880' Bates stamp, indicating it was part of a document production for a House Oversight Committee investigation.
HOUSE_OVERSIGHT_024874.jpg
This document is page 58 of a Cowen Collaborative Insights financial report dated February 25, 2019, analyzing the cannabis and CBD industry. It details strategic updates, retail distribution benchmarking (store counts), and revenue figures for companies including TGOD, HEXO, Neptune, Organigram, Charlotte's Web, and Tilray. While the content is strictly financial analysis, the document bears the Bates stamp 'HOUSE_OVERSIGHT_024874', indicating it was part of a document production for a US House Oversight Committee investigation, likely related to broader financial inquiries.
HOUSE_OVERSIGHT_024833.jpg
This document is page 17 of a financial research report produced by Cowen and Company, dated February 25, 2019. The content focuses on 'Synthetic Cannabis,' detailing the differences between endogenous, phyto-, and synthetic cannabinoids, and includes a table (Figure 9) outlining the medicinal roles of specific compounds like THC and CBD. While the document bears a 'HOUSE_OVERSIGHT' Bates stamp, suggesting it was part of a document production for a congressional investigation, the visible text contains no direct references to Jeffrey Epstein or his associates.
HOUSE_OVERSIGHT_024821.jpg
This Cowen report page discusses the global regulatory landscape for CBD, highlighting developments in Europe and Latin America, and analyzes the U.S. regulatory outlook following the 2018 Farm Bill. It details the shifting oversight from the DEA to the Department of Agriculture while noting continued FDA authority and regulatory uncertainty regarding CBD products.
HOUSE_OVERSIGHT_024820.jpg
This document is page 4 of a Cowen 'Collaborative Insights' market research report dated February 25, 2019. It analyzes the market for cannabinoids (CBD), focusing on synthetic biology production methods, laboratory testing opportunities for life science companies, and the perspectives of drug retailers and insurance payors regarding coverage and sales. The document bears a 'HOUSE_OVERSIGHT_024820' Bates stamp, indicating it was part of a production to the House Oversight Committee, likely related to financial investigations.
HOUSE_OVERSIGHT_024819.jpg
A Cowen equity research report titled 'Cowen's Collective View of CBD - Ahead of the Curve Series,' dated February 25, 2019. The document analyzes the U.S. CBD market, projecting a $16 billion opportunity by 2025, and discusses consumer trends, scientific understanding, and hemp cultivation. The document bears a House Oversight Committee Bates stamp (HOUSE_OVERSIGHT_024819) and a watermark indicating it was intended for Michael Cella at Cowen.
HOUSE_OVERSIGHT_024807.jpg
This document is page 171 from a 2017 report by Ackrell Capital, LLC. It contains a 'Glossary of Terms' specifically related to the cannabis industry (defining terms like THCA, Edible, Flower, Ganja) and relevant regulatory bodies (DEA, FDA, FinCEN). While the document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was produced as part of a Congressional investigation (potentially swept up in a broader request for financial documents), the content itself contains no direct references to Jeffrey Epstein, his associates, or his specific activities.
HOUSE_OVERSIGHT_024794.jpg
This document is page 158 of a Cannabis Investment Report dated December 2017, published by Ackrell Capital, LLC. It profiles four companies operating in the cannabis industry: Rubicon Organics, S2S Development, SC Laboratories, and Scrubbed, providing their locations, websites, and brief business descriptions. The document bears the Bates stamp HOUSE_OVERSIGHT_024794, indicating it is part of a House Oversight Committee production.
HOUSE_OVERSIGHT_024757.jpg
This page from an Ackrell Capital report details capital raised by publicly traded cannabis companies for the year ending September 30, 2017, highlighting that Canadian companies raised significantly more capital than those in the U.S. or Australia. It also provides an overview of the U.S. public capital markets for cannabis, noting that while a few trade on major exchanges like Nasdaq and NYSE, the vast majority are "penny" stocks on the OTC market characterized by high risk and regulatory scrutiny from the SEC and FINRA.
HOUSE_OVERSIGHT_024747.jpg
This document is a page from a 2017 market research report by Ackrell Capital regarding U.S. legalized cannabis market estimates. It includes a bar chart projecting market growth and consumer numbers from 2016 to 2030, contingent on federal legalization milestones. It also provides a sensitivity analysis table showing estimated 2030 market size based on varying population penetration rates and monthly consumer spending. The document bears a House Oversight stamp, suggesting it was part of a larger document production.
HOUSE_OVERSIGHT_024745.jpg
This document is page 109 of a 2017 market research report by Ackrell Capital, LLC, titled 'U.S. and International Cannabis Market Estimates.' It analyzes consumer penetration rates for the cannabis industry, discussing variables such as age groups, state laws (medical vs. recreational), and dispensary networks. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was produced as part of a Congressional investigation, though the text itself contains no direct references to Jeffrey Epstein or his associates.
HOUSE_OVERSIGHT_024739.jpg
This document is page 103 of a 2017 report by Ackrell Capital, LLC regarding U.S. and International Cannabis Market Estimates. It analyzes global market data provided by the UNODC and RAND Corporation, estimating the illegal market value in the billions. It also outlines predictions for U.S. federal legalization, suggesting a pathway involving FDA approvals and state-level adoption. The document bears the Bates stamp HOUSE_OVERSIGHT_024739, indicating it was part of a document production for a House Oversight Committee investigation, likely related to financial probes involving Epstein or associated entities.
HOUSE_OVERSIGHT_024069.jpg
This document is page 58 of a confidential investment memorandum (Control Number 257) outlining 'Certain Investment Considerations' for a venture capital fund. The text details significant risks associated with the fund, specifically noting its focus on life sciences and healthcare technology, the lack of diversification, and the dependency on FDA approvals. It explicitly warns investors that they should be able to withstand a total loss of their investment.
HOUSE_OVERSIGHT_025892.jpg
This document is an informational sheet or press release regarding the pharmaceutical product PRALUENT (alirocumab) manufactured by Sanofi. It details the ODYSSEY Phase 3 clinical trial program, safety information, and side effects. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was part of a document production for a congressional investigation, likely related to pharmaceutical lobbying or healthcare inquiries found within the broader dataset.
HOUSE_OVERSIGHT_025890.jpg
This document appears to be a printout of a news article or press release compilation regarding the FDA approval and market analysis of the Regeneron/Sanofi cholesterol drug, Praluent. It details financial projections, physician surveys, and quotes from executives at Regeneron, Sanofi, and CVS Caremark regarding pricing and accessibility. While the document bears a House Oversight stamp and mentions Donald Trump in a disconnected headline, the content focuses entirely on the pharmaceutical industry.
HOUSE_OVERSIGHT_025889.jpg
This document discusses the approval, benefits, and high cost of a new cholesterol-lowering drug called Praluent, noting its potential expense concerns raised by CVS Caremark executive Troy Brennan. It details the FDA's approval criteria, focusing on patients with genetic conditions or previous heart disease, and mentions the pricing strategy by Regeneron and Sanofi amidst competition from Amgen. The bottom half of the page lists "Recommended by Forbes" article links.
HOUSE_OVERSIGHT_021572.jpg
This document is a Reference Code Sheet (revised 12-19-2006) for the MAOP (Manual of Administrative Operations and Procedures), likely used by the FBI or DOJ to categorize case file data. It provides alphanumeric codes for property, sentence types, agencies (e.g., DEA, FBI, USSS), organized crime roles, government subjects, and specific crime categories including a section for 'Child Predators' (Codes 9A-9I). It serves as a key to interpret coded entries in other documents within the House Oversight file dump.
HOUSE_OVERSIGHT_026364.jpg
This article discusses the new cholesterol drug, Praluent, from Regeneron and Sanofi, focusing on its high price, which is 46% higher than analyst forecasts. It details the FDA's approval for a broader patient group than expected, the potential for wide prescription by doctors despite the label, and the expected resistance from insurance companies who will likely restrict its use. The article also includes commentary from executives at Regeneron and Sanofi, as well as analysts and cardiologists, on the drug's market potential and place alongside existing treatments like statins.
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein entity